Simone Ferrero
A5012645361- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- HIV/AIDS drug development and treatment
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Radiomics and Machine Learning in Medical Imaging
- Mycobacterium research and diagnosis
- Multiple and Secondary Primary Cancers
- AI in cancer detection
- Glycosylation and Glycoproteins Research
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2025
University of Turin
2016-2025
University of Genoa
2002-2025
Ospedale Policlinico San Martino
2010-2025
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
Institute for Health Metrics and Evaluation
2022
University of California, Davis
2021
Medical University of Vienna
2020
Piedmont Reference Center for Epidemiology and Cancer Prevention
2018
PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included bortezomib, thalidomide, dexamethasone (VTD) in patients with multiple myeloma (MM) responding to autologous stem-cell transplantation (auto-SCT). PATIENTS AND METHODS Patients achieving at least very good partial response who had an available molecular marker based immunoglobulin heavy-chain rearrangement...
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Disability and mortality burden of non-communicable diseases (NCDs) have risen worldwide; however, the NCD among adolescents remains poorly described in EU.Estimates were retrieved from Global Burden Diseases, Injuries, Risk Factors Study (GBD) 2019. Causes NCDs analysed at three different levels GBD 2019 hierarchy, for which mortality, years life lost (YLLs), lived with disability (YLDs), disability-adjusted life-years (DALYs) extracted. Estimates, 95% uncertainty intervals (UI), EU Member...
In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem transplantation. Nevertheless, a proportion MCL patients still experience early failure. To identify biomarkers anticipating failure intensive chemotherapy MCL, we performed target resequencing DNA profiling purified tumor samples collected from enrolled prospective FIL-MCL0208 phase 3 trial (high-dose followed by...
Currently, limited data on maternal and neonatal outcomes of pregnant women with infection pneumonia related to SARS coronavirus 2 (SARS-CoV-2) are available. Our report aims describe a case placental swabs positive for the molecular research severe acute respiratory syndrome (SARS-CoV-2 RNA in an asymptomatic woman rhino-pharyngeal swab SARS-CoV-2 who underwent urgent cesarean section our obstetrics unit. Sample collection, processing, laboratory testing were conducted accordance World...
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients follicular lymphoma who responded to induction immunochemotherapy. METHODS randomly assigned treatment-naïve, advanced-stage, high-tumor burden receive standard RM or on the basis metabolic response and molecular assessment minimal residual disease (MRD). The experimental arm used three types therapies: for complete (CMR) MRD-negative patients, observation; CMR MRD-positive...
Currently, treatment allocation of patients with Mantle Cell Lymphoma (MCL) is mainly based on age and medical fitness. The combined MCL International Prognostic Index (MIPI-c) allows to predict prognosis using clinical factors (MIPI) the Ki-67 index. However, high p53 expression as surrogate for TP53 alterations has demonstrated be an independent predictor poor outcome. We aimed define a clear high-risk group combination MIPI, expression/TP53 alteration. A total 684 from prospective...
We here describe a novel method for MYD88L265P mutation detection and minimal residual disease monitoring in Waldenström macroglobulinemia, by droplet digital polymerase chain reaction, bone marrow peripheral blood cells, as well circulating cell-free DNA. Our shows sensitivity of 5.00×10−5, which is far superior to the widely used allele-specific reaction (1.00×10−3). Overall, 291 unsorted samples from 148 patients (133 with 11 IgG lymphoplasmacytic lymphoma 4 IgM monoclonal gammopathy...
We present an innovative approach allowing the identification, isolation, and molecular characterization of disease-related exosomes based on their different antigenic reactivities. The designed strategy could be immediately translated into any disease in which are involved. identification specific markers subsequent association with exosome subtypes, together possibility to engineer target-guided exosome-like particles, represent key for effective adoption clinical practice.
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress on diagnostic front, as well a deeper understanding biology, which affected clinical practice. This, together with increasing variety tools and techniques available, makes it necessary have practical guidance for clinicians perform initial evaluation patients...
Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated morphological and functional features endothelial cells (ECs) derived from bone marrow (BM) patients affected by MM (MMECs). We found that MMECs compared with normal BM ECs (BMECs) showed increased expression syndecan-1. Silencing syndecan-1 RNA interference technique decreased in vitro EC survival, proliferation organization capillary-like structures. vivo, severe combined...
According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address role of B in combination with rituximab (BR), we analyzed outcome 71 patients relapsed/refractory disease, median age 72 years, treated R 375 mg/m(2) day 1 days 2 (dosage ranging from 50 90 mg/m(2)). Patients had previously received number lines treatment (range 1-5). Overall...
Supplemental Digital Content is available in the text